RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) represents the fourth leading cause of cancer-related death in the world. Sorafenib, a first-line chemotherapeutic drug that inhibits cell growth and angiogenesis, has become the standard therapy for inoperable advanced HCC. However, while sorafenib imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xing, Lu, Cheng, Liu, Ziyu, Lin, Yan, Huang, Julu, Lu, Lu, Li, Shuanghang, Huang, Xi, Tang, Minchao, Huang, Shilin, He, Ziqin, She, Xiaomin, Liang, Rong, Ye, Jiazhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252096/
https://www.ncbi.nlm.nih.gov/pubmed/37296859
http://dx.doi.org/10.3390/cancers15112897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252096/
https://www.ncbi.nlm.nih.gov/pubmed/37296859
http://dx.doi.org/10.3390/cancers15112897

Ejemplares similares